Tag:

Galapagos

Latest Headlines

Latest Headlines

Galapagos pulls off a $275M IPO as biotech hopefuls eye $195M more

Belgian biotech Galapagos came through with a $275 million IPO on the strength of its pipeline of immunology treatments, stirring hopes among a new crop of companies that the industry's Wall Street window will remain open through the year.

Galapagos inflates IPO again as AbbVie, J&J jockey for position

Galapagos has ratcheted up its IPO expectations for the second time in a week. The latest maximum offering is just shy of $290 million (€258 million), one-fifth of which is expected to come from potential suitors AbbVie and Johnson & Johnson.

Galapagos dials up IPO target as AbbVie asks for $30M stake

Galapagos has increased the amount it hopes to raise in its upcoming Nasdaq IPO to $230 million (€203 million) after AbbVie placed a provisional order for a $30 million stake. The order adds a subplot to the ongoing speculation about whether AbbVie will take up its $200 million option to buy into Galapagos' rheumatoid arthritis program or acquire the company outright.

Galapagos' arthritis drug shines in another PhIIb study as M&A rumors simmer

Galapagos' AbbVie-partnered rheumatoid arthritis drug hit the mark in another Phase IIb trial, stoking rumors that the Belgian biotech could be in the M&A crosshairs.

Galapagos rolls the dice on a $150M IPO, gambling on rheumatoid arthritis drug

A day after Galapagos rolled out promising results for its oral rheumatoid arthritis drug filgotinib on Tuesday, the Belgian biotech confidently rolled out its plan to raise $150 million in an IPO on Nasdaq. And with topline results for a follow-up study expected in a matter of days, Galapagos says it should be poised to jump into Phase III with a $200 million licensing deal from AbbVie expected before the end of this year.

Galapagos' closely watched rheumatoid arthritis drug filgotinib scores in PhIIb

Belgium's Galapagos says that its oral JAK1 inhibitor filgotinib met its primary and other endpoints in a crucial Phase IIb study for rheumatoid arthritis.

Galapagos registers another setback as J&J dumps anti-inflammatory pact

Eight years after J&J handed over €15 million in an upfront payment to Galapagos to launch a partnership to develop anti-inflammatory drugs, the pharma giant is bowing out--the latest in a series of development setbacks at the European biotech.

J&J punts a pair of new IBD drugs discovered at Galapagos

A few weeks ago Belgium's Galapagos touted some early-stage data on GLPG1205, a new drug for inflammatory bowel diseases which it discovered under a $1 billion-plus partnership deal inked with J&J back in 2007. But today J&J bowed out of the pact for the entire GPR84 program, an effort that includes GLPG1205 and its backup compound GLPG2196.

GlaxoSmithKline backs off from Galapagos' anti-inflammatory hopeful

GlaxoSmithKline has again scaled back its expectations for an anti-inflammatory treatment licensed from Galapagos, calling off any plans for late-stage study after a few Phase II miscues dulled the drug's potential.

GlaxoSmithKline and Galapagos succeed in psoriasis after two setbacks

Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.